Episurf Medical reaches milestone of 250 implants

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by planning of its 250th surgery with the Episealer® implant in the coming weeks.

“This milestone is very important for us, and at the same time, it is important to keep in mind that our clinical data is very strong and the patients are truly being helped by our technology. That said, it is obviously very encouraging that we have cut the time between our 50 intervals in half. Increasing our sales is important and this is a clear sign of the fact that the Episealer technology is gaining increased acceptance. This is a good day for Episurf Medical and I want to extend my gratitude to all orthopaedic surgeons, patients and employees“, says Pål Ryfors, CEO Episurf Medical.

"It is reassuring to note that the orthopedic profession seems to catch on and note the good clinical results and the very few complications and adopt the Episealer technology. It starts to look as an exponential increase in users and usage of the Episealer device", says Prof. Leif Ryd, Senior Medical Advisor Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical 

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.35 CET on 16 Augusti 2017.